Association between two functional polymorphisms in the MMP-2 promoter and lung cancer incidence in Asian population: a meta-analysis study

Khafaei, Mostafa; Gharechahi, Javad; Sadeghi, Morteza

doi:10.58209/ijbc.14.2.61

Volume 14, Issue 2 ( June 2022 2022) Iranian Journal of Blood and Cancer 2022, 14(2): 61-67 | Back to browse issues page

‎ 10.58209/ijbc.14.2.61

Mendeley

Zotero

RefWorks

Khafaei M, Gharechahi J, Sadeghi M. Association between two functional polymorphisms in the MMP-2 promoter and lung cancer incidence in Asian population: a meta-analysis study. Iranian Journal of Blood and Cancer 2022; 14 (2) :61-67
URL: http://ijbc.ir/article-1-1201-en.html

Association between two functional polymorphisms in the MMP-2 promoter and lung cancer incidence in Asian population: a meta-analysis study

Mostafa Khafaei¹

, Javad Gharechahi¹

, Morteza Sadeghi ^*

1- Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
2- Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran , ms.sadeghi@yahoo.com

Abstract: (1708 Views)

Background: Numerous experiments have been performed to determine the relationship between the Matrix metalloproteinase-2 (MMP-2) -1306C/T and -735C/T polymorphisms and the prevalence and progression of lung cancer in diverse populations. However, due to the small sample size and the different results of previous studies, we decided to perform a general meta-analysis on all previous studies about mmp-2 polymorphism and lung cancer in Asian population.
Methods: A complete literature review was conducted within the ISI Web of Knowledge, google scholar, and PubMed databases for studies about MMP-2 polymorphism and lung cancer published from 2002 to 2020. A meta-analysis was conducted, which included more than 2884 cases and 2768 controls. The pooled odds ratio (OR) and 95% confidence intervals (CI) were used for dominant, recessive, and co-dominant MMP-9 genotypes to assess the strength of the association.
Results: A significant correlation was found between the MMP2 C 1306T polymorphism and lung cancer risk (C vs T: OR=1.705, P=0.029; CC vs CT+ TT: OR=1.16, 95% P=0.000) and for MMP2 C 735T polymorphism (C vs T: OR=1.433, P=0.151; CC vs CT+TT: OR=1.698, P=0.000).
Conclusion: The present meta-analysis revealed a significant association between the MMP-2-735C/T and MMP-9-1562 C/T polymorphisms and the risk of lung cancer in Asian population.

Keywords: Matrix metalloproteinase-2, Lung cancer, Asian, Polymorphism

Full-Text [PDF 811 kb] (376 Downloads)

: Original Article | Subject: Genetics
Received: 2021/11/7 | Accepted: 2022/06/4 | Published: 2022/06/28

References

1. Chambers,A.F. and Matrissian,L.M. Changing views of the role of matrix metalloproteinase in metastasis. J. Natl Cancer Inst.1997;89,1260-1270. [DOI:10.1093/jnci/89.17.1260]

2. Curran,S. and Murray,G.I. Matrix metalloproteinases in tumor invasion and metastasis. J. Pathol. 1999;189, 300 --308. [DOI:10.1002/(SICI)1096-9896(199911)189:33.0.CO;2-C]

3. Stamenkovic,I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 2000;10, 415-433. [DOI:10.1006/scbi.2000.0379]

4. Xie,T.X., Wei,D., Liu,M., Gao,A.C., Ali-Osman,F., Sawaya,R. and Huang,S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene. 2004;23, 3550-3560. [DOI:10.1038/sj.onc.1207383]

5. Ross,J.S., Kaur,P., Sheehan,C.E., Fisher,H.A., Kaufman,R.A.Jr and Kallakury,B.V. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod. Pathol. 2003;16,198-205. [DOI:10.1097/01.MP.0000056984.62360.6C]

6. Bodey,B., Bodey,B.Jr., Groger,A.M., Siegel,S.E. and Kaiser,H.E. Invasion and metastasis: the expression and significance of matrix metalloproteinases in carcinomas of the lung. In Vivo. 2001;15, 175-180.

7. Egeblad,M. and Werb,Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer. 2002; 2,161-174. [DOI:10.1038/nrc745]

8. McCaswley,L.J. and Matrisian,L.M. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 2001;13, 534-540. [DOI:10.1016/S0955-0674(00)00248-9]

9. Sternlicht,M.D. and Werb,Z. Matrix metalloproteinase. In Kreis,T. and Vale,R. (eds) Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins. Oxford University Press, New York, 1999, pp. 503-603.

10. Galateau-Salle,F.B., Luna,R.E., Horiba,K., et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum. Pathol. 2000; 31, 296-305. [DOI:10.1016/S0046-8177(00)80242-7]

11. Schmalfeldt,B., Prechtel,D., Harting,K., et al. (2001) Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 2001;7, 2396-2404.

12. Bergers,G., Brekken,R., Mcmahon,G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000; 2,737-744. [DOI:10.1038/35036374]

13. Itoh,T., Tanioka,M., Yoshida,H., Yoshioka,T., Nishimoto,H. and Itohara,S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998;58,1048-1051.

14. Price,S.J., Greaves,D.R. and Watkins,H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J. Biol. Chem. 2000;276, 7549-7558. [DOI:10.1074/jbc.M010242200]

15. Harendza,S., Lovett,D.H., Panzer,U., Lukacs,Z., Kuhnl,P. and Stahl,R.A. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J. Biol. Chem. 2003;278, 20490-20499. [DOI:10.1074/jbc.M211536200]

16. Yu,C., Zhou,Y., Miao,X., Xiong,P., Tan,W. and Lin,D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res. 2004;64, 7622-7628. [DOI:10.1158/0008-5472.CAN-04-1521]

17. Yu,C., Pan,K., Xing,D., Liang,G., Tan,W., Zhang,L. and Lin,D. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res. 2002;62, 6430-6433.

18. Miao,X., Yu,C., Tan,W., Xiong,P., Liang,G., Lu,W. and Lin,D. A functional polymorphism in the matrix metalloproteinase-2 gene promoter ( 1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res. 2003;63,3987-3990.

19. Zhou,Y., Yu,C., Miao,X., Tan,W., Liang,G., Xiong,P., Sun,T. and Lin,D. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis. 2003;25, 399-404. [DOI:10.1093/carcin/bgh020]

20. Lin,S.C., Lo,S.S., Liu,C.J., Chung,M.Y., Huang,J.W. and Chang,K.W. Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J. Oral Pathol. Med. 2004;33,405-409. [DOI:10.1111/j.1600-0714.2004.00231.x]

21. Xu,E., Lai,M., Lv,B., Xing,X., Huang,Q. and Xia,X. A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem. Biophys. Res. Commun. 2004;324, 999-1003. [DOI:10.1016/j.bbrc.2004.09.150]

22. Chunyuan Yu, Kaifeng Pan, Deyin Xing, Gang Liang, Wen Tan, Lian Zhang, and Dongxin Lin. Advances in Brief Correlation between a Single Nucleotide Polymorphism in the Matrix Metalloproteinase-2 Promoter and Risk of Lung Cancer. Cancer Res. 2002;62:6430-6433.

23. Zhou Y, Yu C, Miao X, Wang Y, Tan W, Sun T, Zhang X, Xiong P, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis. 2005;26(6):1117-21. [DOI:10.1093/carcin/bgi057]

24. Ayşegül B, Veysi GH, Muzaffer M, Irfan D, Azra A, Hulyam K. Is a single nucleotide polymorphism a risk factor for lung cancer in the matrix metalloproteinase-2 promoter? Mol Biol Rep. 2011;38(3):1469-74. [DOI:10.1007/s11033-010-0253-5]

25. Keshvary Ravan H, Kouhkan F, Sazgar H. Single Nucleotide Polymorphisms of MMP2 Gene Promoter on the Risk of Development and Metastasis of lung Cancer. Armaghane-danesh 2017; 22 (1): 104-117

26. Rollin J, Régina S, Vourc'h P, Iochmann S, Bléchet C, Reverdiau P, Gruel Y. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer. 2007;56(2):273-80. [DOI:10.1016/j.lungcan.2006.11.021]

27. Brummer,O., Athar,S., Riethdorf,L., Loning,T. and Herbst,H. Matrix metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch. 1999;435, 566-573. [DOI:10.1007/s004280050442]

28. Caudroy,S., Polette,M., Tournier,J.M., Burlet,H., Toole,B., Zucker,S. and Birembaut,P. Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary. J Histochem Cytochem. 1999; 47(12):1575-80. [DOI:10.1177/002215549904701209]

29. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135-49. [DOI:10.1200/JCO.2000.18.5.1135]

30. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-74. [DOI:10.1038/nrc745]

31. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 2002;29:78-86. [DOI:10.1053/sonc.2002.31528]

32. Chetty C, Rao JS, Lakka SS. Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma. Pharmacogenomics. 2011;12:535-46. [DOI:10.2217/pgs.10.207]

33. Wang J, Cai Y. Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis. Tumour Biol. 2012;33(6):1819-28 [DOI:10.1007/s13277-012-0441-0]

34. McColgan P, Sharma P. Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer. 2009;125:1473-8. [DOI:10.1002/ijc.24441]

35. Li X, Liu C, Ran R, et al. Matrix metalloproteinase family gene polymorphisms and lung cancer susceptibility: an updated meta-analysis. J Thorac Dis. 2020;12(3):349-362. [DOI:10.21037/jtd.2020.01.25]

36. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 2000;19:623. [DOI:10.1016/S0945-053X(00)00102-5]

37. Price S, Greaves D, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem. 2001;276:7549. [DOI:10.1074/jbc.M010242200]

Send email to the article author

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb